Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Aging

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IgG Glycosylation-Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Molecular arms races at the virus-host splicing interface and their pathogenic implications.

Frontiers in microbiology·2026

Same author

Beyond barrier function: keratinocytes as orchestrators of humoral immunity.

Immunity & inflammation·2026

Same author

Cell-Targeted Inhibition of CaMK4 Suppresses Tertiary Lymphoid-like Structure Development in Lupus-Prone Mice.

International journal of molecular sciences·2026

Same author

Fat bursts T cells to drive joint inflammation.

Cell metabolism·2026

Same author

Extracellular heme:DNA complexes promote oxidative stress and inflammation during lupus-associated hemolysis.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026

Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026

Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026

Same journal

Complement in Traumatic Brain Injury: Linking Acute Injury to Chronic Neurodegeneration.

European journal of immunology·2026

Same journal

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026

Same journal

Methodological Insights Into T-Cell Activation: CD3/CD28 Versus PMA/Ionomycin Stimulation.

European journal of immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 20, 2025

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

Reverse aging to treat lupus.

Wenliang Pan¹, George C Tsokos¹

¹Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.

European Journal of Immunology

|July 20, 2024

Summary

This summary is machine-generated.

Senescent CD4+ T cells, particularly CD4+CD57+ cells, are linked to systemic lupus erythematosus (SLE) activity, driven by interleukin-15. Senolytic drug treatment reduced autoimmune pathology in lupus-prone mice, suggesting new SLE therapies.

Keywords:

Aging BCL‐2 ISG Senescence Systemic lupus erythematosus T cells

More Related Videos

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Related Experiment Videos

Last Updated: Jun 20, 2025

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

Immunology
Autoimmunity
Cellular senescence

Background:

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by immune system dysregulation.
Abnormalities in T-cell subsets and function are implicated in SLE pathogenesis.
Accumulation of senescent T cells, specifically CD4+ T cells, is increasingly recognized as a contributor to SLE development.

Purpose of the Study:

To investigate the role of senescent CD4+ T cells in systemic lupus erythematosus (SLE).
To explore the association between CD4+CD57+ senescent T cells, disease activity, and interleukin-15 in SLE patients.
To evaluate the therapeutic potential of senolytic drugs in a preclinical model of SLE.

Main Methods:

Flow cytometry was used to quantify CD4+CD57+ senescent T cells in SLE patients.
Interleukin-15 levels were measured and correlated with T-cell subsets and disease activity.
Lupus-prone mice were treated with a senolytic drug, and subsequent autoimmune pathology was assessed.

Main Results:

An expanded pool of CD4+CD57+ senescent T cells was identified in patients with SLE.
The expansion of these senescent T cells correlated with SLE disease activity and was associated with elevated interleukin-15 levels.
Senolytic drug treatment in lupus-prone mice led to a significant reduction in autoimmune pathology.

Conclusions:

Expanded CD4+CD57+ senescent T cells, influenced by interleukin-15, are implicated in SLE pathogenesis.
Senolytic therapy demonstrates potential as a novel therapeutic strategy for managing SLE.
Targeting senescent T cells may offer a new avenue for treating patients with systemic lupus erythematosus.